3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
45
Neoplasm Metastasis
6
Glioma
6
Glioblastoma
6
Neoplasms
5
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Ovarian Neoplasms
3
Liposarcoma
3
Diffuse Intrinsic Pontine Glioma
3
Astrocytoma
3
Recurrence
2
Prostatic Neoplasms
2
Meningioma
2
Medulloblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Breast Cancer Metastatic
2
Venous Thromboembolism
1
Triple Negative Breast Neoplasms
1
Thymus Neoplasms
1
Sarcoma, Synovial
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Interventions
Cyclophosphamide
53
Etoposide
33
Temozolomide
28
Irinotecan
28
Melphalan
25
Filgrastim
25
Topotecan
24
Carboplatin
24
3-Iodobenzylguanidine
23
Isotretinoin
20
Granulocyte Colony-Stimulating Factor
17
sargramostim
16
humanized 3F8 anti-GD2 monoclonal antibody
16
dinutuximab
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
fludarabine
15
Vincristine
15
Doxorubicin
15
Cisplatin
15
Peripheral Blood Stem Cell Transplantation
14
Interleukin-2
14
Busulfan
13
naxitamab
12
Thiotepa
12
Radiotherapy
12
aldesleukin
11
fludarabine phosphate
10
etoposide phosphate
8
Mesna
8
Ifosfamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroblastoma
×
ribociclib
×
Clear all
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled